DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Argininosuccinate is an investigational drug.
There have been 4 clinical trials for Argininosuccinate. The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2016.
The most common disease conditions in clinical trials are Mesothelioma, Wounds and Injuries, and Reperfusion Injury. The leading clinical trial sponsors are Polaris Group, Washington University School of Medicine, and Polaris Pharmaceuticals, Inc.
There are three hundred and ninety-eight US patents protecting this investigational drug and two international patents.
Recent Clinical Trials for Argininosuccinate
|ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma||Polaris Pharmaceuticals, Inc.||Phase 2|
|ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma||Washington University School of Medicine||Phase 2|
|Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin||Polaris Group||Phase 2/Phase 3|
Top disease conditions for Argininosuccinate
Top clinical trial sponsors for Argininosuccinate
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Argininosuccinate||Start Trial||Methods of expressing products in mammalian cells||INTREXON CEU, INC. (Blacksburg, VA)||Start Trial|
|Argininosuccinate||Start Trial||Methods and compositions for multiplex PCR||LIFE TECHNOLOGIES CORPORATION (Carlsbad, CA)||Start Trial|
|Argininosuccinate||Start Trial||Peptides and peptide/active compound conjugates for renal targeting||MERCK PATENT GMBH (Darmstadt, DE)||Start Trial|
|Argininosuccinate||Start Trial||Compositions of engineered human arginases and methods for treating cancer||AERase, Inc. (Austin, TX)||Start Trial|
|Argininosuccinate||Start Trial||Methods and compositions for multiplex PCR||Life Technologies Corporation (Carlsbad, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Argininosuccinate||World Intellectual Property Organization (WIPO)||WO2012027533||2030-08-25||Start Trial|
|Argininosuccinate||European Patent Office||EP2702170||2031-04-28||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|